Targeted Therapy for Older Patients with Non-Small Cell Lung Cancer: Systematic Review and Guidelines from the French Society of Geriatric Oncology (SoFOG) and the French-Language Society of Pulmonology (SPLF)/French-Language Oncology Group (GOLF)

被引：12

作者：

Greillier, Laurent ^{[1
,2
,3
]}

Gauvrit, Manon ^{[4
]}

Paillaud, Elena ^{[5
,6
,7
]}

Girard, Nicolas ^{[2
,3
,8
,9
]}

Montegut, Coline ^{[7
,10
]}

Boulahssass, Rabia ^{[7
,11
,12
]}

Wislez, Marie ^{[2
,3
,13
,14
]}

Pamoukdjian, Frederic ^{[7
,15
,16
]}

Corre, Romain ^{[7
,17
]}

Cabart, Mathilde ^{[18
]}

Caillet, Philippe ^{[5
,7
,19
]}

Belaroussi, Yaniss ^{[4
,20
,21
]}

Frasca, Matthieu ^{[4
,22
,23
]}

Noize, Pernelle ^{[4
,24
,25
]}

Wang, Pascal ^{[13
]}

Mebarki, Soraya ^{[5
,7
]}

Mathoulin-Pelissier, Simone ^{[4
,23
]}

Couderc, Anne-Laure ^{[7
,10
,26
]}

机构：

[1] Aix Marseille Univ, Multidisciplinary Oncol & Therapeut Innovat Dept, CNRS INSERM CRCM, APHM Marseille France, F-13009 Marseille, France

[2] French Language Soc Pulm SPLF, F-75006 Paris, France

[3] French Language Oncol Grp GOLF, F-75006 Paris, France

[4] Inst Bergonie Clin Res Plateform Older Patients C, Inserm CIC1401, F-33076 Bordeaux, France

[5] HEGP Paris Canc Inst CARPEM, Dept Geriatr, Geriatr Oncol Clin, APHP, F-75015 Paris, France

[6] Univ Paris, Fac Hlth, F-75006 Paris, France

[7] French Soc Geriatr Oncol SoFOG, F-63122 Ceyrat, France

[8] Thorax Inst Curie Montsouris, F-75014 Paris, France

[9] UVSQ Paris, F-78000 Saclay, France

[10] Internal Med Geriatr & Therapeut Unit, APHM, F-13009 Marseille, France

[11] Univ Hosp Nice, Coordinat Unit, Geriatr Oncol Rehabil & Auton Dept, F-06000 Nice, France

[12] Univ Onco Age, Nice Sophia Antipolis, F-06100 Nice, France

[13] Hop Cochin, APHP, Oncol Thorac Unit, Dept Pulmonol, F-75014 Paris, France

[14] Univ Paris, Ctr Rech Cordeliers, Sorbonne Univ, INSERM Team Inflammat Complement & Canc, F-75006 Paris, France

[15] Avicenne Hosp, APHP, Geriatr Dept, F-93000 Bobigny, France

[16] Sorbonne Paris Nord Univ, INSERM UMR S942, Cardiovasc Markers Stressed Condit MASCOT, F-93000 Bobigny, France

[17] Cornouaille Hosp, Pulmonol Dept, F-29000 Quimper, France

[18] Inst Bergonie, Oncol Dept, F-33076 Bordeaux, France

[19] Univ Paris Est, INSERM U955 IRMB, F-94000 Creteil, France

[20] Univ Bordeaux, Leveque Hosp Univ Bordeaux, Dept Thorac Surg Haut, F-33000 Bordeaux, France

[21] Bordeaux Populat Hlth Res Ctr, INSERM, EPICeNE Team, UMR 1219, F-33000 Bordeaux, France

[22] Palliat Med Dept CHU, F-33000 Bordeaux, France

[23] Bordeaux Univ, Bordeaux Populat Hlth Ctr Rech, Equipe Canc & Environm EPICeNE, U1219, F-33000 Bordeaux, France

[24] CHU Bordeaux, Clin Pharmacol Dept, F-33000 Bordeaux, France

[25] Univ Bordeaux, INSERM BPH U1219, Team Pharm Epidemiol, F-33000 Bordeaux, France

[26] Aix Marseille Univ, CNRS EFS ADES, F-13015 Marseille, France

来源：

CANCERS | 2022年 / 14卷 / 03期

关键词：

lung cancer; targeted therapy; efficacy; toxicity; safety; quality of life; geriatric assessment; PHASE-II TRIAL; ELDERLY-PATIENTS; OPEN-LABEL; 1ST-LINE TREATMENT; 2ND-LINE THERAPY; ERLOTINIB; GEFITINIB; MUTATION; CHEMOTHERAPY; EFFICACY;

D O I：

10.3390/cancers14030769

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Simple Summary Targeted therapy has become essential in the treatment of non-small cell lung cancer (NSCLC). There are currently no guidelines for older patients who are frailer with regard to this type of treatment. Two learned societies, the French Society of Geriatric Oncology (SoFOG) and the French-language Society of Pulmonology (SPLF)/French-language Oncology Group (GOLF), joined forces to conduct a systematic review of the literature from May 2010 to May 2021 regarding the efficacy, toxicity, and feasibility of targeted therapy in older patients with NSCLC. Guidelines were then drawn up to enable clinicians to adapt the type of targeted therapy proposed according to the oncological and geriatric profile of the older patient with NSCLC. Systematic molecular profiling and targeted therapy (TKI) have changed the face of Non-Small Cell Lung Cancer (NSCLC) treatment. However, there are no specific recommendations to address the prescription of TKI for older patients. A multidisciplinary task force from the French Society of Geriatric Oncology (SoFOG) and the French Society of Pulmonology/Oncology Group (SPLF/GOLF) conducted a systematic review from May 2010 to May 2021. Protocol registered in Prospero under number CRD42021224103. Three key questions were selected for older patients with NSCLC: (1) to whom TKI can be proposed, (2) for whom monotherapy should be favored, and (3) to whom a combination of TKI can be proposed. Among the 534 references isolated, 52 were included for the guidelines. The expert panel analysis concluded: (1) osimertinib 80 mg/day is recommended as a first-line treatment for older patients with the EGFR mutation; (2) full-dose first generation TKI, such as erlotinib or gefitinib, is feasible; (3) ALK and ROS1 rearrangement studies including older patients were too scarce to conclude on any definitive recommendations; and (4) given the actual data, TKI should be prescribed as monotherapy. Malnutrition, functional decline, and the number of comorbidities should be assessed primarily before TKI initiation.

引用

页数：24

共 83 条

[1] Erlotinib and bevacizumab in elderly patients ≥75 years old with non-small cell lung cancer harboring epidermal growth factor receptor mutations [J].

Aoshima, Yoichiro ;

Karayama, Masato ;

Inui, Naoki ;

Yasui, Hideki ;

Hozumi, Hironao ;

Suzuki, Yuzo ;

Furuhashi, Kazuki ;

Fujisawa, Tomoyuki ;

Enomoto, Noriyuki ;

Nakamura, Yutaro ;

Mikamo, Masashi ;

Matsuura, Shun ;

Kusagaya, Hideki ;

Kaida, Yusuke ;

Uto, Tomohiro ;

Hashimoto, Dai ;

Matsui, Takashi ;

Asada, Kazuhiro ;

Suda, Takafumi .

INVESTIGATIONAL NEW DRUGS, 2021, 39 (01) :210-216

[2] Gefitinib as First-line Treatment in Elderly Epidermal Growth Factor Receptor-mutated Patients With Advanced Lung Adenocarcinoma: Results of a Nagano Lung Cancer Research Group Study [J].

Asami, Kazuhiro ;

Koizumi, Tomonobu ;

Hirai, Kazuya ;

Ameshima, Shingo ;

Tsukadaira, Akihiro ;

Morozumi, Nobutoshi ;

Morikawa, Akio ;

Atagi, Shinji ;

Kawahara, Masaaki .

CLINICAL LUNG CANCER, 2011, 12 (06) :387-392

[3] Real-Life Efficacy of Osimertinib in Pretreated Octogenarian Patients with T790M-Mutated Advanced Non-small Cell Lung Cancer [J].

Auliac, Jean-Bernard ;

Saboundji, Karima ;

Andre, Michel ;

Madelaine, Jeannick ;

Quere, Gilles ;

Masson, Philippe ;

Vergnenegre, Alain ;

Lamy, Regine ;

Raymond, Stephane ;

Chiappa, Anne-Marie ;

Hauss, Pierre-Alexandre ;

Fournel, Pierre ;

Corre, Romain ;

Chouaid, Christos .

TARGETED ONCOLOGY, 2019, 14 (03) :307-314

[4] Impact of MET inhibitors on survival among patients with non-small cell lung cancer harboring MET exon 14 mutations: a retrospective analysis [J].

Awad, Mark M. ;

Leonardi, Giulia C. ;

Kravets, Sasha ;

Dahlberg, Suzanne E. ;

Drilon, Alexander ;

Noonan, Sinead A. ;

Camidge, D. Ross ;

Ou, Sai-Hong, I ;

Costa, Daniel B. ;

Gadgeel, Shirish M. ;

Steuer, Conor E. ;

Forde, Patrick M. ;

Zhu, Viola W. ;

Fukuda, Yoko ;

Clark, Jeffrey W. ;

Janne, Pasi A. ;

Mok, Tony ;

Sholl, Lynette M. ;

Heist, Rebecca S. .

LUNG CANCER, 2019, 133 :96-102

[5]

Balducci L, 2013, INTERD T GERONT GERI, V38, P61, DOI 10.1159/000343586

[6] Randomized Phase III Trial of Maintenance Bevacizumab With or Without Pemetrexed After First-Line Induction With Bevacizumab, Cisplatin, and Pemetrexed in Advanced Nonsquamous Non-Small-Cell Lung Cancer: AVAPERL (MO22089) [J].

Barlesi, Fabrice ;

Scherpereel, Arnaud ;

Rittmeyer, Achim ;

Pazzola, Antonio ;

Tur, Neus Ferrer ;

Kim, Joo-Hang ;

Ahn, Myung-Ju ;

Aerts, Joachim G. J. V. ;

Gorbunova, Vera ;

Vikstrom, Anders ;

Wong, Elaine K. ;

Perez-Moreno, Pablo ;

Mitchell, Lada ;

Groen, Harry J. M. .

JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (24) :3004-+

[7] Efficacy and Safety of ALK Tyrosine Kinase Inhibitors in Elderly Patients with Advanced ALK-Positive Non-Small Cell Lung Cancer: Findings from the Real-Life Cohort [J].

Bedas, Aseel ;

Peledc, Nir ;

Rabinovich, Natalie Maimon ;

Mishaeli, Moshe ;

Shochat, Tzippy ;

Zer, Alona ;

Rotem, Ofer ;

Allen, Aaron M. ;

Bar, Jair ;

Dudnik, Elizabeth .

ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (05) :275-282

[8] Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study [J].

Brueckl, Wolfgang M. ;

Achenbach, H. Jost ;

Ficker, Joachim H. ;

Schuette, Wolfgang .

BMC CANCER, 2018, 18

[9] Brigatinib versus Crizotinib in ALK-Positive Non-Small-Cell Lung Cancer [J].

Camidge, D. R. ;

Kim, H. R. ;

Ahn, M. -J. ;

Yang, J. C. -H. ;

Han, J. -Y. ;

Lee, J. -S. ;

Hochmair, M. J. ;

Li, J. Y. -C. ;

Chang, G. -C. ;

Lee, K. H. ;

Gridelli, C. ;

Delmonte, A. ;

Garcia Campelo, R. ;

Kim, D. -W. ;

Bearz, A. ;

Griesinger, F. ;

Morabito, A. ;

Felip, E. ;

Califano, R. ;

Ghosh, S. ;

Spira, A. ;

Gettinger, S. N. ;

Tiseo, M. ;

Gupta, N. ;

Haney, J. ;

Kerstein, D. ;

Popat, S. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (21) :2027-2039

[10] Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study [J].

Camidge, D. Ross ;

Bang, Yung-Jue ;

Kwak, Eunice L. ;

Iafrate, A. John ;

Varella-Garcia, Marileila ;

Fox, Stephen B. ;

Riely, Gregory J. ;

Solomon, Benjamin ;

Ou, Sai-Hong I. ;

Kim, Dong-Wan ;

Salgia, Ravi ;

Fidias, Panagiotis ;

Engelman, Jeffrey A. ;

Gandhi, Leena ;

Jaenne, Pasi A. ;

Costa, Daniel B. ;

Shapiro, Geoffrey I. ;

LoRusso, Patricia ;

Ruffner, Katherine ;

Stephenson, Patricia ;

Tang, Yiyun ;

Wilner, Keith ;

Clark, Jeffrey W. ;

Shaw, Alice T. .

LANCET ONCOLOGY, 2012, 13 (10) :1011-1019

← 1 2 3 4 5 6 7 8 9 →